 |
|
|
|
 |
|
|
| Article 1 to 8 out of 8 concerning ImmunoVaccine Technologies Inc. (IVT)
|
-
ImmunoVaccine Technologies Appoints New CFO
(30 Sep 2009)
Immunovaccine Technologies (IVT) announced that it has appointed Gary Dodge, CA, as Chief Financial Officer.Reporting to president and CEO Dr. Randal Chase, Mr. Dodge will oversee IVT's accounting and financing activities. Mr. Dodge also becomes a ...
-
ImmunoVaccine Technologies Licenses Immunotope’s Breast, Ovarian and Prostate Cancer Antigens
(16 Jul 2009)
ImmunoVaccine Technologies Inc. (IVT) has entered into an agreement to exclusively license seven cancer antigens from Immunotope Inc., an antigen discovery company. These proprietary antigens specifically target breast, ovarian and prostate cancers. ...
-
ImmunoVaccine Technologies DepoVax Shows Positive Results for Cancer and Infectious Diseases
(06 Oct 2008)
ImmunoVaccine Technologies (IVT) patented depot vaccine formulation, DepoVax(TM) is showing positive pre-clinical results, with single-dose efficacy achieved in therapeutic cancer and several infectious disease vaccine models. The results of this ...
-
ImmunoVaccine Technologies Broadens Its Patent Protection to Japan
(07 Aug 2008)
ImmunoVaccine Technologies Inc. (IVT) announced receipt of patent approval from the Japanese Patent Office for its vaccine platform. The specific patent, Vaccines with enhanced immune response and methods for their preparation, claims broad ...
-
ImmunoVaccine Technologies Inc. to Acquire Immunotope Inc.
(12 Dec 2007)
ImmunoVaccine Technologies Inc. (IVT) has signed a binding memorandum of understanding to acquire Immunotope Inc., a Pennsylvania-based biotechnology company developing immunotherapy products for the treatment and prevention of cancer and infectious ...
-
ImmunoVaccine Technologies Inc. Completes Scale-Up of VacciMax to Commercially Relevant Scale
(03 Dec 2007)
ImmunoVaccine Technologies Inc. (IVT) announced that it has successfully scaled-up the manufacturing process for its vaccine platform, Vaccimax(R). This work validates the suitability of the platform for commercial applications in therapeutic cancer ...
-
Pharmexa grants PADRE license to ImmunoVaccine Technologies Inc.
(25 Aug 2006)
Pharmexa has entered into a license agreement with ImmunoVaccine Technologies Inc. (IVT) of Halifax, Nova Scotia for the use of PADRE® immunostimulatory peptide(s) with IVT's VacciMax® vaccines. IVT has a non-exclusive right to use PADRE® in ...
-
ImmunoVaccine Technologies Receives European Patent Allowance
(29 Sep 2005)
ImmunoVaccine Technologies Inc. (IVT) announced that it has received a patent allowance from the European patent office for their patent application entitled 'Vaccines with enhanced immune response and methods for their preparation'. The patent ...
Additional information
ImmunoVaccine Technologies Inc. (IVT)
Halifax, Nova Scotia, Canada
Company
|
|
|
|
|
|
Top
